Related references
Note: Only part of the references are listed.Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy
Christine M. Parseghian et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Joana Vidal et al.
CLINICAL CANCER RESEARCH (2023)
Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance)
Kanwal Raghav et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer
Maria F. Arisi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Effects of the number of neoadjuvant therapy cycles on clinicaloutcomes, safety, and survival in patients with metastatic colorectalcancer undergoing metastasectomy br
Yung-Sung Yeh et al.
ONCOLOGY RESEARCH (2022)
Colon Cancer, Version 2.2021
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment
Hong-Hwa Chen et al.
FRONTIERS IN ONCOLOGY (2021)
Precision oncology in metastatic colorectal cancer - from biology to medicine
Federica Di Nicolantonio et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Liquid Biopsy: From Discovery to Clinical Application
Catherine Alix-Panabieres et al.
CANCER DISCOVERY (2021)
Case Report: Vemurafenib Treatment in Brain Metastases of BRAFS365L -Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection
Jianing Jiang et al.
FRONTIERS IN ONCOLOGY (2021)
Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol
Shang-Hung Chen et al.
BMC CANCER (2019)
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Aparna R. Parikh et al.
NATURE MEDICINE (2019)
Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
NaNa Keum et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini et al.
JAMA ONCOLOGY (2019)
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
Giovanni Crisafulli et al.
ESMO OPEN (2019)
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
S. Siena et al.
ANNALS OF ONCOLOGY (2018)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
T. Yoshino et al.
ANNALS OF ONCOLOGY (2018)
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab
Rodrigo A. Toledo et al.
ONCOTARGET (2017)
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
Alan P. Venook et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping
Su-Jin Shin et al.
PLOS ONE (2017)
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
J. Vidal et al.
ANNALS OF ONCOLOGY (2017)
SPSB1-mediated HnRNP A1 ubiquitylation regulates alternative splicing and cell migration in EGF signaling
Feng Wang et al.
CELL RESEARCH (2017)
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer
Ming-Yii Huang et al.
TRANSLATIONAL ONCOLOGY (2016)
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
Ji Yun Lee et al.
ONCOTARGET (2016)
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology
Maider Ibarrola-Villava et al.
ONCOTARGET (2016)
Detection of KRAS, NRAS and BRAF bymass spectrometry - a sensitive, reliable, fast and cost-effective technique
Mark Kriegsmann et al.
DIAGNOSTIC PATHOLOGY (2015)
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer
Dominik P. Modest et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The genomic landscape of response to EGFR blockade in colorectal cancer
Andrea Bertotti et al.
NATURE (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Clinical Relevance of Alterations in Quantity and Quality of Plasma DNA in Colorectal Cancer Patients: Based on the Mutation Spectra Detected in Primary Tumors
Jen-Kou Lin et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Tumour heterogeneity and the evolution of polyclonal drug resistance
Rebecca A. Burrell et al.
MOLECULAR ONCOLOGY (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
New Developments in the Second-Line Treatment of Metastatic Colorectal Cancer: Potential Place in Therapy
Dirk Arnold et al.
DRUGS (2013)
Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis
Cindy Kin et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2013)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
Liquid biopsy: monitoring cancer-genetics in the blood
Emily Crowley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
Thomas H. Cartwright
CLINICAL COLORECTAL CANCER (2012)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Diaz et al.
NATURE (2012)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Alberto Bardelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers
M. Mimeault et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2007)
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
Eric Van Cutsem et al.
EUROPEAN JOURNAL OF CANCER (2006)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
About the possible origin and mechanism of circulating DNA - Apoptosis and active DNA release
M Stroun et al.
CLINICA CHIMICA ACTA (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
